Galectin Therapeutics (GALT) Current Assets (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Current Assets of $15.7 million for Q1 2026, up 68.99% year-over-year from $9.3 million in Q1 2025, and down 19.27% quarter-over-quarter from $19.4 million in Q4 2025.
Galectin Therapeutics (GALT) Current Assets (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $15.7 million for Q1 2026.
- In Q1 2026, Current Assets rose 68.99% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $15.7 million (up 68.99% YoY), while the FY2025 annual figure was $19.4 million, up 12.66% from the prior year.
- Current Assets for Q1 2026 stood at $15.7 million, down from $19.4 million in the prior quarter.
- The five-year high for Current Assets was $33.5 million in Q1 2022, with the low at $9.3 million in Q1 2025.
- The 5-year median for Current Assets is $19.6 million (2023), against an average of $21.0 million.
- The sharpest annual moves came in 2025 and 2026: Current Assets sank 63.53% in 2025, then jumped 68.99% in 2026.
- Galectin Therapeutics' Current Assets stood at $20.6 million in 2022, then surged by 34.83% to $27.7 million in 2023, then sank by 37.74% to $17.3 million in 2024, then increased by 12.66% to $19.4 million in 2025, then declined by 19.27% to $15.7 million in 2026.
- Business Quant data shows GALT's Current Assets at $15.7 million in Q1 2026, $19.4 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 15.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.69 Mn |
| Dec 31, 2025 | 19.44 Mn |
| Sep 30, 2025 | 12.73 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Mar 31, 2025 | 9.29 Mn |
| Dec 31, 2024 | 17.25 Mn |
| Sep 30, 2024 | 28.67 Mn |
| Jun 30, 2024 | 27.29 Mn |
| Mar 31, 2024 | 25.46 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Sep 30, 2023 | 21.61 Mn |
| Jun 30, 2023 | 19.47 Mn |
| Mar 31, 2023 | 19.55 Mn |
| Dec 31, 2022 | 20.55 Mn |
| Sep 30, 2022 | 17.12 Mn |
| Jun 30, 2022 | 25.79 Mn |
| Mar 31, 2022 | 33.51 Mn |
| Dec 31, 2021 | 41.82 Mn |
| Sep 30, 2021 | 38.00 Mn |
| Jun 30, 2021 | 33.33 Mn |